Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Akebia Announces Nine Abstracts Accepted for Presentation at the American Society of Nephrology Kidney Week 2019 Annual Meeting


Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that nine abstracts, including several associated with vadadustat and Auryxia® (ferric citrate), have been accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting. ASN Kidney Week 2019 will take place in Washington, D.C. from November 5 to November 10, 2019 at the Walter E. Washington Convention Center. Conference attendees can meet with Company representatives at Booth #2307 to discuss Akebia's presentations.

Four posters and presentations are associated with vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) in global Phase 3 development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis dependent (DD)-CKD patients and non-dialysis dependent (NDD)-CKD patients. All abstracts selected for presentation are summarized below and are available from ASN on the Kidney Week abstracts archive: https://www.asn-online.org/education/kidneyweek/archives/.

Vadadustat Oral and Poster Presentations:

Ferric Citrate and Additional Oral and Poster Presentations:

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vadadustat
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor currently in global Phase 3 development for the treatment of anemia due to CKD. Vadadustat is designed to mimic the physiologic effect of altitude on oxygen availability. At higher altitudes, the body responds to lower oxygen availability with stabilization of hypoxia-inducible factor, which can lead to increased red blood cell production and improved oxygen delivery to tissues. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority.

About Auryxia® (ferric citrate) Tablets
Auryxia (ferric citrate) was approved by the FDA on September 5, 2014 for the control of serum phosphorus levels in adult patients with CKD on dialysis and approved by the FDA on November 6, 2017 for the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. For more information about Auryxia and the U.S. full prescribing information, please visit www.auryxia.com.

IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) CONTRAINDICATION
AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis.

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Most common adverse reactions with AURYXIA were:

SPECIFIC POPULATIONS

To report suspected adverse reactions, contact Akebia Therapeutics at 1-844-445-3799.
Please see full Prescribing Information.


These press releases may also interest you

at 11:11
BlueCat, the Adaptive DNStm company, today announced that it has appointed Barry Saadatmand as Senior Vice President of Global Sales. Saadatmand brings with him approximately two decades of experience leading high-performance sales teams at...

at 11:10
Assured Consulting Solutions, LLC (ACS) is proud to announce our achievement of ISO 9001:2015 certification. ISO 9001:2015 is the world's most widely recognized quality management standard. This standard and certification was selected specifically to...

at 11:10
Prodoscoretm, a sales employee visibility company, today announced that DTiQ, a leading provider of intelligent video-based surveillance and loss prevention services, has sustained higher sales productivity by incorporating Prodoscore as an integral...

at 11:07
GoDaddy Inc. , the company that empowers everyday entrepreneurs, received a 100 percent on the Human Rights Campaign's 2020 Corporate Equality Index (CEI), the nation's premier benchmarking survey and report measuring corporate policies and practices...

at 11:05
HID Global, a worldwide leader in trusted identity solutions, announces Björn Lidefelt has been named President and CEO. Björn joins the company after serving as Chief Commercial Officer (CCO) at HID parent company ASSA ABLOY, where he oversaw...

at 11:05
Alpha Holdings, Inc. (KOSDAQ: 117670) ("Alpha"), the largest stockholder of OncoSec Medical Incorporated ("OncoSec"), with an approximate 15.1% ownership stake, today announced that it has renewed its alternative financing proposal and provided a...



News published on 24 october 2019 at 08:05 and distributed by: